← Eichor
Condition: Refractory Indolent B Cell Non Hodgkin Lymphoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Refractory Indolent B Cell Non Hodgkin Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT05672251MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
Phase 1/Phase 2 · 1 location(s) · Beijing Mabworks Biotech Co., Ltd. · NCT04110301Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
Phase 1 · 1 location(s) · Lapo Alinari · NCT05755087CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
Phase 1 · 1 location(s) · Nathan Denlinger · NCT06209619A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemi
Phase 2 · 1 location(s) · Shayna Sarosiek, MD · NCT06986174Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant
Phase 2 · 3 location(s) · City of Hope Medical Center · NCT07365306Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
Phase 2 · 1 location(s) · University of Washington · NCT06784726Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of R
Phase 1 · 8 location(s) · National Cancer Institute (NCI) · NCT06015880Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma
Phase 2 · 7 location(s) · Mayo Clinic · NCT06386315A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
Phase 1/Phase 2 · 27 location(s) · BioInvent International AB · NCT03571568A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Len
Phase 3 · 169 location(s) · Regeneron Pharmaceuticals · NCT06149286ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07098364Epcoritamab-CAR T Cells for Large B-cell Lymphomas
Phase 2 · 1 location(s) · Abramson Cancer Center at Penn Medicine · NCT06458439Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refracto
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT04223765Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Mali
Phase 1 · 2 location(s) · Sumithira Vasu · NCT05418088SynKIR-310 for Relapsed/Refractory B-NHL
Phase 1 · 5 location(s) · Verismo Therapeutics · NCT06544265
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.